In addition, BBR suppresses the toll-like receptor 9 (TLR9)-myeloid differentiation factor 88 (MyD88)–nuclear factor kappa-B (NF-κB) pathway and partly reverses doxorubicin (Dox)-exacerbated breast cancer metastasis (Zheng et al., 2021). This evidence concerns the gene TLR9 and breast cancer.